CenterBook Partners LP increased its holdings in Regeneron Pharmaceuticals (NASDAQ:REGN) by 10.9% in the third quarter, making it their 6th largest position. Regeneron reported strong quarterly earnings, surpassing analyst estimates for EPS and revenue. Analysts currently have a “Moderate Buy” rating on the stock with an average price target of $793.81.
This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.
Regeneron Pharmaceuticals, Inc. $REGN Shares Purchased by CenterBook Partners LP
CenterBook Partners LP increased its holdings in Regeneron Pharmaceuticals (NASDAQ:REGN) by 10.9% in the third quarter, making it their 6th largest position. Regeneron reported strong quarterly earnings, surpassing analyst estimates for EPS and revenue. Analysts currently have a “Moderate Buy” rating on the stock with an average price target of $793.81.